Akshit Chitkara

Jul 30, 2024 | mdpi.com | Akshit Chitkara |Yue Yin |Maitreyee Rai |Sushanth Sreenivasan

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Sep 7, 2023 | mdpi.com | Akshit Chitkara |Muhammad Arsalan Bakhtiar |Ibrahim Halil Sahin |Ibrahim Şahin |Dennis J. Hsu

3. Results 3.1. Study CharacteristicsTwo of the six trials selected evaluated trastuzumab deruxtecan, and one evaluated trastuzumab plus lapatinib. One trial evaluated pertuzumab plus trastuzumab emtansine, while one evaluated trastuzumab plus tucatinib, and one evaluated trastuzumab plus pyrotinib (Table 2). Regarding prior lines of treatment, the median number of prior lines was two and three in two trials and four and five in one trial each.